Canntab Therapeutics

Putting the ‘Medical’ into Medicinal Cannabis

This profile is part of a paid investor education campaign.*


Canntab Therapeutics (CSE:PILL, OTC:CTABF, FSE:TBF1is bringing pharmaceutical expertise to the cannabis market through the development of its patent-pending Canntab Extended Release (XR) Tablets™. Using proprietary extended release technology previously developed by the company, Canntab is producing a safe, stable and standardized delivery method for cannabis particles (CBD and THC) that is not burdened with the negative effects associated with smoking, edibles or topicals.

The proprietary extended release technology provides lasting effects of 12 to 18 hours, making the Canntab XR Tablets™ an appealing alternative to other intake methods. The XR Tablets™ have also been designed for doses of 2.5 mg, 5.0 mg or 10.0 mg, making dosing and prescribing much more straightforward for the medical community.

Based in Markham, Ontario, the company will be expanding their operations as they move into an independent 10,000 square-foot area within the FSD Pharma facility in Cobourg, Ontario. From there, the company will be producing and distributing its products. Additionally, Canntab has also entered into a licensing agreement with Emblem Corp, a licensed producer (LP), under which Emblem will develop and market Canntab’s XR Tablets™ in Canada. Beyond Canada, Canntab has entered into a joint venture with Vitacann, a subsidiary of Queensland Bauxite (ASX:QBL), under which the companies will work towards the approval of sales of Canntab XR Tablets™ in Australia as well as their export to Asia.  Also beyond Canada, Canntab has signed non-binding Letters of Intent with NewCanna S.A.S Bogota in Columbia and Labsco Promedic SA in Mexico, covering the sale and distribution in Columbia, Chile, Paraguay, Spain and Mexico.

Canntab is led by a management team with proven experience in both the pharmaceutical and capital market spaces. The company’s leaders, Jeff Renwick and Richard Goldstein, have been working with their team to develop Canntab’s proprietary technology for almost a decade and have numerous patents for unique drug formulations, making them leaders within the cannabis pharmaceutical space. The management team is also supported by board members Vitor Fonseca and Sheldon Inwentash, both of which provide extensive insight into financial aspects and business development.

Company Highlights

  • Proprietary Canntab XR Tablets™ provide safe, fast-acting and long-lasting alternative to current cannabis intake methods
  • A strong intellectual property portfolio with 13 patents pending in the United States and Canada pertaining to the formulation of tablets including instant release, extended release, flash melt and bi-layered. The products will be available in 2.5g, 5g and 10g tablets.
  • An application to become a Licensed Producer (Non Grower) under the Access to Cannabis for Medical Purposes Regulations and has confirmation from Health Canada that its application had been received.
  • Licensing agreement with Emblem Corp, leading Canadian LP to develop and market XR Tablets™
  • Reaching a milestone in its development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC, OTCQX: EMMBF). Dissolution testing indicated that the Extended Release Tablets released cannabinoids consistently over a 12-hour period. Given these positive test results, Canntab is manufacturing pivotal batches of these tablets for further clinical testing. This will lead to the filing of dossiers with regulatory agencies around the world for approval of Canntab’s unique solid oral dose delivery systems.
  • Co-locating in 10,000-square-foot area within the FSD Pharma facility in Cobourg, Ontario for production and distribution of products
  • Health Canada’s approval of Canntab’s ‘420 Therapeutics’ brand of Cannabis wellness products. These capsules are made with purified organic hemp seed oil and are an easy and convenient way to enjoy the health benefits of hemp oil. This is an important milestone achievement for Canntab in their move towards manufacturing full spectrum hemp derived CBD.
  • Entered into joint venture with Australian company Vitacann, seeking approval for sale of Canntab XR Tablets™ within Australia and export to Asia
  • Management team with noted experience in both pharmaceutical and capital markets spaces
  • Announcement of the signing of a non-binding Letter of Intent with NewCanna S.A.S of Bogota, Colombia for the establishment of a significant bi-lateral relationship covering the sale and distribution of Canntab’s products in Colombia, Chile, Paraguay and Spain with a one-time, non-refundable license fee ($2-million US) payable to Canntab by NewCanna.
  • Announcement of the signing of a non-binding Letter of Intent with Labsco Promedic SA for the establishment of a joint venture relationship covering, on an exclusive basis, the sales and distribution of Canntab products in Mexico.

The North American Medicinal Cannabis Market

Legalization of the use of medicinal cannabis has been spreading across North America. In the US, regulation sits at the state level, and the November 2016 elections saw four additional states allow or expand access to medical cannabis. Meanwhile, in Canada, medicinal cannabis is federally regulated, and the country is moving towards recreational regularization by summer of 2018.

Within the realm of medical cannabis, increasing numbers of patients are making use of the drug to address symptoms associated with arthritis, chronic pain, diabetes, epilepsy, glaucoma and other conditions. In June of 2017, Health Canada reported a total of over 200,000 registered medicinal cannabis users, over 10,000 more users than the previous month. Meanwhile, in the US, there are an estimated 1.2 million registered patients, with more coming on board as additional states legalize medicinal use. As patients explore the potential issues associated with different delivery methods for CBD or THC, there is an opportunity for Canntab to enter the market as a provider of safe, standardized extended release cannabis tablets.

Providing an Alternate Delivery Method

The issues behind current delivery methods

For the average cannabis user, there are a number of delivery methods available beyond smoking and edibles. Each of these are either accompanied by adverse effects or are proven to be relatively ineffective once the cannabis particles travel through the digestive system or pass through the liver.

When it comes to smoking, the associated issues include a lack of dosage management, stigma perpetuation and the detrimental impacts to the respiratory system. Edibles or orally ingested oils, on the other hand, are becoming more popular, but have unreliable onset times and are significantly diluted as they pass through the gastrointestinal (GI) tract. In addition, topicals that are produced with oils are typically used for localized pain, and are not capable of addressing a broader selection of conditions.

Canntab XR Tablets™

In light of the current obstacles to effective cannabis delivery, Canntab has developed a product line of solid oral dose delivery systems including extended release (XR), flash melt, immediate release, modified release and bi-layered tablet solutions that provide a variety of cannabinoid and terpenoid blends in exacting dosages. A clear and sustainable competitive advantage with 13 patents pending.

Using the experience garnered from creating generic drugs in the past, Canntab has also created its XR Tablets™ with proprietary extended release technology that allows patients to experience their effects for between 12 and 18 hours, something unheard of in other delivery methods.

canntab xr tablets

Canntab’s oral dose delivery systems will come in 2.5 mg, 5.0 mg or 10.0 mg formats, making it much easier for doctors and patients to manage the dosage.  The Canntab XR Tablets™ can also have various combinations of CBD and THC percentages—depending on the condition and requirements pertinent to the patient.

Deploying Canntab XR Tablets™ to the Market


Canntab has deployed a co-location strategy in which it shares space with licensed producers renowned for the quality of their product. To this effect, the company has completed a co-location agreement with leading licensed producer, FSD Pharma. This will help us complete our facility in Coburg, expanding our capacity while controlling inputs and deferring capital costs by co-locating with producers.

Distribution of Canntab products

As part of their business model, Canntab has entered into a licensing agreement with Emblem Corp, a Canadian licensed producer of dry flowers and oils, in October 2017. This agreement provides Canntab with a distribution channel for its products—once the Canadian government grants the approval of sale—and access to Emblem’s existing customer base of over 2,200 patients.

As it awaits its approval of sale within Canada, Canntab is also exploring distribution opportunities within Australia and the US and has signed letters of intent to market its products within those countries. To this effect, Canntab has signed an exclusive joint venture agreement with VitaCann, a subsidiary Medical Cannabis, a company owned by Queensland Bauxite. Together, Canntab and VitaCann will be working towards having the Canntab XR Tablets™ formally approved for sale in Australia and prepared for export to Asia.

Similarly, Canntab has announced the signing of a non-binding Letter of Intent with NewCanna S.A.S of Bogota, Colombia for the establishment of a significant bi-lateral relationship covering the sale and distribution of Canntab’s products in Colombia, Chile, Paraguay and Spain with a one-time, non-refundable license fee ($2-million US) payable to Canntab by NewCanna.

In addition, Canntab has also announced the signing of a non-binding Letter of Intent with Labsco Promedic SA for the establishment of a joint venture relationship covering, on an exclusive basis, the sales and distribution of Canntab products in Mexico.


Jeff Renwick—CEO, Director

Previously the President and CEO of Orbus Pharma, a generic drug development and manufacturing company. Prior to that Indukern Chemie AG, a Swiss pharma company. More than 20 years of experience in drug formulation and business development. Independent director of 2 public TSX companies.

Richard Goldstein—CFO, Director

Founder of First Republic Capital, co-founder at Fraser Mackenzie, previously executive vice-president and Head of Investment Banking at Standard Securities. Over 26 years of experience in investment banking and institutional sales and trading. MBA in finance from McMaster University.

Tommy Larocque—Procurement Manager

More than 15 years of procurement management in the pharmaceutical industry. Previously was procurement manager and compliance officer for Orbus Pharma Inc. More than 15 years of Pharmaceutical plant GMP construction experience.

Board of Directors

Jeff Renwick—CEO, Director

Richard Goldstein—CFO, Director

Barry Polisuk—Corporate Secretary and Chairman of the Board

Has been a partner at Garfinkle Biderman, specializing in corporate and commercial work, including securities. Holds a LL.N cum laude and a Quebec civil law degree, both from the University of Ottawa.

Vitor Fonseca—Director

Vitor Fonseca is VP and Treasurer of Romspen Investment Corporation, Canada’s largest non-bank commercial real estate lender. He has held senior finance and operational positions in the real estate, private equity and service-oriented industries. He holds an MBA from the, Rotman School of Business, a CPA-CGA designation and is a member of the Institute of Corporate Directors.

Advisory Board

Sabrina Ramkellawan—Clinical Trials

Sabrina is the Vice President of the Clinical Research Association of Canada and the President of The Canadian Institute for Medical Advancement. She has 20 years of experience conducting clinical trials, including 7 studies on Cannabinoids and as such is renowned as a leader in the field.

Hamish Sutherland—Advisor

Hamish is one of a select few who has real experience in building a successful cannabis company, as the founding COO for Bedrocan Canada, delivering over $400-million in returns for shareholders. He was responsible for the first legal international transfer of live cannabis plant material from Holland to Canada, and was accountable for the “greenfield” construction and commissioning of Bedrocan’s state-of-the-art automated facility, which was acquired by Tweed (now Canopy Growth) to become the leading cannabis company in Canada. Hamish is a Professional Engineer in Ontario, earned his MBA from Schulich, and is the active Chair of the Little Geeks Foundation. He loves basketball, sailing and helping youth achieve their potential.

Dr. Eric Hatashita, MD, CCFOP, FCFP—Advisor

Dr. Eric Hatashita attended the University of Toronto Medical School and rose to be Chief Resident at Mt Sinai Hospital. Invited by the Kingdom of Saudi Arabia to assist in developing their Residency Training program, he lived and taught medicine overseas starting in 1996. During this time, he was chosen to become Family Physician to the Saudi Royal Family of King Abdullah 2000-2005 in recognition of his clinical excellence. Returning to Toronto with his family in 2005, he brings over 30 years of diverse medical experience to a private concierge medical practice, Regal Health Services Inc holding the highest honours in Family Medicine, the “FCFP.”

More than 20 years of experience in biotechnology, pharma and supplement industries. Has extensive cross-border transactional experience including IP aspects of corporate transactions.


*Disclaimer: The profile provides information which was sourced and approved by Canntab Therapeutics in order to help investors learn more about the company. Canntab Therapeutics is a client of the Investing News Network (INN). The company’s campaign fees pay for INN to create and update this profile page, to which links are placed on and channel newsletters.

The company description, investment highlights and catalysts were sourced by INN and approved by the company. INN does not guarantee the accuracy or thoroughness of the information contained on this page.

INN does not provide investment advice and the information on profile should not be considered a recommendation to buy or sell any security.

INN does not endorse or recommend the business, products, services or securities of any company profiled.

Readers should conduct their own research for all information publicly available concerning the company.